Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Previous researches have indicated that miR-4317 was aberrantly expressed in several tumors. However, the potential role of miR-4317 in breast cancer is still unclear. The aim of this study was to investigate the potential role of miR-4317 in breast cancer. The relative expression levels of miR-4317 were detected in breast cancer tissues and cell lines using qRT-PCR analysis. The Kaplan–Meier survival curve and multivariate Cox regression analyses were used to investigate the prognostic significance of miR-4317 in breast cancer. CCK-8 and Transwell assays were performed to evaluate the effects of miR-4317 on cell proliferation, migration, and invasion. The results showed that miR-4317 expression was decreased in breast cancer tissues and cell lines. Downregulation of miR-4317 was significantly associated with lymph node metastasis, TNM stage, and poor prognosis. Overexpression of miR-4317 inhibited proliferation, migration, and invasion of breast cancer cells, while downregulation of miR-4317 exhibited the opposite effects. MYD88 may be a direct target of miR-4317. The results suggest miR-4317 may play a tumor suppressor role in breast cancer and inhibit proliferation, migration, and invasion of breast cancer cells by targeting MYD88. The findings provide novel evidence of miR-4317 as a potential prognostic biomarker and therapeutic target for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

miRNAs:

MicroRNAs

mimic NC:

Mimic negative controls

cDNA:

Complementary DNA

qRT-PCR:

Quantitative real-time PCR

CCK-8:

Cell counting kit-8

ANOVA:

Analysis of variance

NSCLC:

Non-small cell lung cancer

References

  1. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50.

    Article  PubMed  Google Scholar 

  2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

    Article  Google Scholar 

  3. Zhou D, Ouyang Q, Liu L, et al. Chemotherapy modulates endocrine therapy-related resistance mutations in metastatic breast cancer. Transl Oncol. 2019;12(5):764–74.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Qian CN, Mei Y, Zhang J. Cancer metastasis: issues and challenges. Chin J Cancer. 2017;36(1):38.

    Article  PubMed  PubMed Central  Google Scholar 

  5. de Castro Sant’ Anna C, Junior AGF, Soares P, et al. Molecular biology as a tool for the treatment of cancer. Clin Exp Med. 2018;18(4):457–64.

    Article  PubMed  Google Scholar 

  6. Jiang L, Zhang X, Geradts J, et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. Clin Exp Med. 2019;19(3):377–84.

    Article  CAS  PubMed  Google Scholar 

  7. Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018;18(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  9. Chen H, Yang Y, Wang J, Shen D, Zhao J, Yu Q. miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1. Oncol Lett. 2018;15(5):6361–7.

    PubMed  PubMed Central  Google Scholar 

  10. Sun X, Cui S, Fu X, Liu C, Wang Z, Liu Y. MicroRNA-146-5p promotes proliferation, migration and invasion in lung cancer cells by targeting claudin-12. Cancer Biomark. 2019;25(1):89–99.

    Article  PubMed  Google Scholar 

  11. Guo H, Zhang L. MicroRNA-30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7. Exp Ther Med. 2019;18(1):209–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Liu Y, Duan N, Duan S. MiR-29a inhibits glioma tumorigenesis through a negative feedback loop of TRAF4/Akt signaling. Biomed Res Int. 2018;2018:2461363.

    PubMed  PubMed Central  Google Scholar 

  13. Huang GH, Shan H, Li D, Zhou B, Pang PF. MiR-199a-5p suppresses tumorigenesis by targeting clathrin heavy chain in hepatocellular carcinoma. Cell Biochem Funct. 2017;35(2):98–104.

    Article  CAS  PubMed  Google Scholar 

  14. Hannafon BN, Cai A, Calloway CL, et al. miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer. 2019;19(1):642.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhao C, Ling X, Li X, Hou X, Zhao D. MicroRNA-138-5p inhibits cell migration, invasion and EMT in breast cancer by directly targeting RHBDD1. Breast Cancer. 2019;26(6):817–25.

    Article  PubMed  Google Scholar 

  16. Zhao XG, Hu JY, Tang J, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10(7):479.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sand M, Skrygan M, Sand D, et al. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013;351(1):85–98.

    Article  CAS  PubMed  Google Scholar 

  18. Janiszewska J, Szaumkessel M, Kostrzewska-Poczekaj M, et al. Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma. PLoS ONE. 2015;10(12):e0144924.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Danza K, De Summa S, Pilato B, et al. Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. J Transl Med. 2014;12:319.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol. 2015;12(3):147–62.

    Article  PubMed  Google Scholar 

  21. Hart NH, Galvao DA, Saunders C, et al. Mechanical suppression of osteolytic bone metastases in advanced breast cancer patients: a randomised controlled study protocol evaluating safety, feasibility and preliminary efficacy of exercise as a targeted medicine. Trials. 2018;19(1):695.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Liu L, Tian YC, Mao G, Zhang YG, Han L. MiR-675 is frequently overexpressed in gastric cancer and enhances cell proliferation and invasion via targeting a potent anti-tumor gene PITX1. Cell Signal. 2019;62:109352.

    Article  CAS  PubMed  Google Scholar 

  23. Zhang L, Xu J, Yang G, Li H, Guo X. miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer. Oncol Res. 2018;26(6):949–57.

    Article  PubMed  Google Scholar 

  24. Yang W, Bai J, Liu D, et al. MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis. Gene. 2018;647:13–20.

    Article  CAS  PubMed  Google Scholar 

  25. Wu M, Li X, Liu Q, Xie Y, Yuan J, Wanggou S. miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1. Cancer Manag Res. 2019;11:3099–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li X, Xu M, Ding L, Tang J. MiR-27a: a novel biomarker and potential therapeutic target in tumors. J Cancer. 2019;10(12):2836–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Li C, Zhang J, Ma Z, Zhang F, Yu W. miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther. 2018;11:4087–95.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Li WJ, Xie XX, Bai J, Wang C, Zhao L, Jiang DQ. Increased expression of miR-1179 inhibits breast cancer cell metastasis by modulating Notch signaling pathway and correlates with favorable prognosis. Eur Rev Med Pharmacol Sci. 2018;22(23):8374–82.

    PubMed  Google Scholar 

  29. Zhang J, He Y, Yu Y, et al. Upregulation of miR-374a promotes tumor metastasis and progression by downregulating LACTB and predicts unfavorable prognosis in breast cancer. Cancer Med. 2018;7(7):3351–62.

    Article  CAS  PubMed Central  Google Scholar 

  30. Zhang J, Tian ZL, Zhang WT, et al. Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2019;23(7):2803–8.

    CAS  PubMed  Google Scholar 

  31. He X, Chen SY, Yang Z, et al. miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res. 2018;37(1):230.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Hu X, Zhang M, Miao J, Wang X, Huang C. miRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. Cell Biol Int. 2018;42(8):923–30.

    Article  CAS  PubMed  Google Scholar 

  33. Xu X, Yin Y, Tang J, et al. Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification. Cell Death Dis. 2017;8(10):e3124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–9.

    Article  CAS  PubMed  Google Scholar 

  35. Xiang F, Ni Z, Zhan Y, et al. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer. Tumour Biol. 2016;37(5):6017–25.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Yuwei Sheng, Rong Hu and Yi Zhang have contributed equally to this work.

Authors and Affiliations

  1. Department of Thyroid and Breast Surgery, Shanghai First People’s Hospital Baoshan Branch, No. 101, North Tongtai Road, Shanghai, 200940, China

    Yuwei Sheng, Yi Zhang & Wenjie Luo

  2. Department of Pharmacy, Shanghai First People’s Hospital Baoshan Branch, Shanghai, 200940, China

    Rong Hu

Authors
  1. Yuwei Sheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjie Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YS, RH, and YZ initiated and designed the experiments, analyzed data, and drafted and revised the manuscript. WL conceived and designed the manuscript. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Wenjie Luo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Availability of data and materials

The dataset supporting the conclusions of this article is included within the article.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Shanghai First People’s Hospital Baoshan Branch, and written informed consent was signed by all patients.

Consent for publication

Written informed consent for publication was obtained from each participant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheng, Y., Hu, R., Zhang, Y. et al. MicroRNA-4317 predicts the prognosis of breast cancer and inhibits tumor cell proliferation, migration, and invasion. Clin Exp Med 20, 417–425 (2020). https://doi.org/10.1007/s10238-020-00625-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-020-00625-4

Keywords

Search

Navigation